Broadly neutralizing antibodies (bnAbs) have been considered to be potent therapeutic tools and potential vaccine candidates to enable protection against various clades of human immunodeficiency virus (HIV). The generation of bnAbs has been associated with enhanced exposure to antigen, high viral load and low CD4+ T cell counts, among other factors. However, only limited data are available on the generation of bnAbs in viraemic non-progressors that demonstrate moderate to high viraemia. Further, since HIV-1 subtype C viruses account for more than 50 % of global HIV infections, the identification of bnAbs with novel specificities is crucial to enable the development of potent tools to aid in HIV therapy and prevention. In the present study, we analysed and compared the neutralization potential of responses in 70 plasma samples isolated from ART-naïve HIV-1 subtype C-infected individuals with various disease progression profiles against a panel of 30 pseudoviruses. Among the seven samples that exhibited a neutralization breadth of !70 %, four were identified as 'elite neutralizers', and three of these were from viraemic non-progressors while the fourth was from a typical progressor. Analysis of the neutralization specificities revealed that none of the four elite neutralizers were reactive to epitopes in the membrane proximal external region (MPER), CD4-binding site and V1V2 or V3 glycan. However, two of the four elite neutralizers exhibited enhanced sensitivity towards viruses lacking N332 glycan, indicating high neutralization potency. Overall, our findings indicate that the identification of potent neutralization responses with distinct epitope specificities is possible from the as yet unexplored Indian population, which has a high prevalence of HIV-1 subtype C infection.
INTRODUCTION
The elicitation of potent neutralizing antibodies is the principal correlate of protection for most preventable vaccines [1] . For rapidly evolving pathogens like human immunodeficiency virus (HIV), neutralizing antibodies elicited by vaccination or during natural infection are largely strain-specific and therefore non-protective against globally circulating viral strains [2] . However, 10-20 % of HIV-infected individuals elicit highly potent broadly neutralizing antibodies (bnAbs) that hold promise as potent therapeutic and prophylactic agents. Recent studies have shown that passively transferred bnAbs protect against simian/human immunodeficiency virus (SHIV) infection in non-human primates [3] and control viraemia in HIV-infected individuals with chronic infection [4] [5] [6] . In recent years, major advancements in HIV vaccine research have resulted in the isolation and characterization of next-generation bnAbs that are able to neutralize around 70 to 90 % of circulating HIV-1 strains in vitro [7] Downloaded from www.microbiologyresearch.org by IP: 54.70.40.11
On: Thu, 04 Jul 2019 04:39:13 from a subset of HIV-1-infected individuals referred to as 'broad neutralizers'. Post-seroconversion, the development of bnAbs generally takes 2-4 years [8] . Based on the different target sites on HIV-1 envelope protein [9] , bnAbs are categorized into five types: the CD4-binding site (CD4bs) on the gp120 subunit (bnAbs b12, VRC01-03, NIH45-46 and 3BNC117), quaternary epitopes in the V1V2 region on the gp120 trimer (PG9, PG16, PGT141145, PGDM1400 and CAP256-VRC26.25), glycan-dependent epitopes in the V3 loop (PGT series of bnAbs), the membrane proximal external region (MPER) of the gp41 subunit (bnAbs 2F5, 4E10 and 10E8) and a cleavage-dependent epitope at the gp41-gp120 interface of the Env trimer (PGT151 and PGT152) [10] . Studies show that the development of bnAbs is significantly associated with the duration of infection, high viral load, low CD4 counts, partial restoration of B-cell sub-populations and higher frequency of follicular helper T cells among typical progressors [8, 11, 12] . Further, recent studies have also demonstrated broad and potent neutralization responses in viraemic controllers [13] . However, limited information is available on bnAb generation in viraemic non-progressors who maintain stable CD4+ T cell coungts with moderate to high levels of plasma viraemia for more than 7 years postinfection [14] . Furthermore, given the high burden of HIV-1 subtype C infection and the limited number of studies on the identification of bnAbs in India [15] [16] [17] [18] , studying the neutralizing antibody responses and their specificities in Indian population has become an urgent necessity. Based on the above, the present study aims to analyse comparative neutralization responses among viraemic controllers, viraemic nonprogressors and typical progressors, and further aid in the identification of bnAbs with unique specificities in HIV-1 subtype C-infected individuals from southern India.
RESULTS
Identification and classification of broadly neutralizing plasma samples A total of 70 ART-naïve HIV-1 subtype C-infected individuals with different disease progression profiles, i.e. viraemic controllers (n=20), viraemic non-progressors (n=21) and typical progressors (n=29), were enrolled in the study. The participants were characterized in terms of clinical history, duration of infection, CD4+ T cell count and plasma viral load ( Table 1) . None of the plasma samples showed background activity for antiretroviral drugs, as determined by a neutralization assay with murine leukaemia virus. All of the plasma samples (n=70) were screened against a panel of 11 heterologous tier II viruses (Table S1 , available in the online version of this article), including major subtypes A, B, C, G, AC, BC and AE, for the determination of neutralization response. For each sample, the neutralization breadth and potency were calculated against the HIV-1 isolates from the heterologous 11-virus (Tables 2, 3 and 4) . The neutralization breadth of a specimen was defined as the number of viruses neutralized at ID 50 titre >100. The neutralization potency of a specimen was defined as the geometric mean titre (GMT) of the ID 50 against all viruses tested. The individual plasma titres of <20 were assigned a value of 20 for the GMT calculations.
Based on the neutralization results observed in the preliminary screening, the plasma samples were categorized into two levels: the 'low neutralizers' that neutralized <50 % of the tested viruses and/or had a neutralization potency <100, and the 'top neutralizers' that neutralized !50 % of the tested viruses and/or had a neutralization potency !100 (Table S2) .
HIV-1 viraemic non-progressors elicit broad and potent neutralization activity For the identification of broadly neutralizing activity, samples with 'top' neutralization were tested against an extended panel of 19 tier IB and II viruses (Table S3) comprising Indian subtype C and African subtype A and C strains (n=19). A heat map was generated based on the overall neutralization breadth and potency of 28 top neutralizers against HIV-1 isolates from both panels (30 viruses in total; Fig. 1 ). The samples that neutralized !70 % of the tested viruses and exhibited a geometric mean ID 50 >500 were considered to be broad neutralizers. Of the 28 top neutralizers, 4 were identified as broad neutralizers, and 3 of these were from viraemic non-progressors -LT*VNP03, LT*VNP04 and LT*VNP20 -and 1 was from a typical progressor -TP*14 ( Fig. 1) . Moreover, two of the three viraemic nonprogressors (LT*VNP03 and LT*VNP20) exhibited top neutralization potency (GMT ID 50 >700).
Comparative analysis of the neutralization breadth and potency among different population groups on the 11-virus Individual plasma titres of 20 were assigned a value of <20 for the geometric mean titre calculations, which indicates a lack of neutralization activity. ID 50 values refer to the reciprocal dilution that conferred 50 % neutralization of viruses in a TZM-bl assay. Individual plasma titres of <20 were assigned a value of 20 for the geometric mean titre calculations, which indicates a lack of neutralization activity. ID 50 values refer to the reciprocal dilution that conferred 50 % neutralization of viruses in a TZM-bl assay. (Fig. 2a, b) . The differential breadth and potency were also compared between viraemic non-progressors (n=12) and typical progressors (n=14) on the 30-virus panel. The results demonstrated that 67 % (8 out of 12) of the viraemic non-progressors and 21 % (3 out of 14) of the typical progressors neutralized >50 % of the 30-virus panel. In addition, a significantly higher neutralization breadth (Fig. 2c , P=0.006) and potency (Fig. 2d, P=0 .037) was observed among the viraemic non-progressors as compared to the typical progressors.
The broadly neutralizing antibodies from broad neutralizers exhibit unique specificities
Lack of MPER activity The four samples exhibiting broad neutralization were analysed for the presence of MPER-specific activity by ELISA and MPER-mediated neutralization response using a peptide competition neutralization assay [for the neutralization assay, peptides were pre-incubated with plasma samples prior to incubation with virus (Indian C HIV-25711-2.4 virus) in a standard neutralization assay format]. Both experiments illustrated that none of the samples were reactive to MPER, with there being no more than a threefold change in the ID 50 titre with the MPER-treated plasma samples in the neutralization assay (Table 5) .
Non-specificity to CD4-binding site antibodies The specificity of the plasma samples to the CD4-binding site was analysed by ELISA using resurfaced stabilized core 3 (RSC3) protein that was designed for the selective binding of CD4bs antibodies. The results showed that none of the broad neutralizers were reactive for RSC3 protein.
To further investigate CD4bs-mediated neutralizing activity in plasma, we examined the ability of an RSC3 to compete and deplete the plasma ID 50 titre. Our data showed that none of the RSC3-treated plasma samples demonstrated a greater than threefold change in the ID 50 titre (Table 5) .
Lack of V1V2 glycan-specific response Plasma-neutralizing antibodies that target V1V2 epitope were tested by using N160A and R166A point-mutant viruses in a standard neutralization assay. None of the samples demonstrated a greater than threefold change in ID 50 titre against point-mutant viruses (Table 6) .
No strong evidence of V3 glycan-specific antibody response For the identification of V3 epitope-specific activity, plasma samples from four broad neutralizers were tested against N301A and N332A point-mutant viruses in a standard neutralization assay. None of the samples demonstrated a greater than threefold change in ID 50 titre against point-mutant viruses ( Table 6 ). The peptide competition assays also revealed similar results ( Table 7) .
Absence of N332 glycan is associated with enhanced neutralization response The N-linked glycan positions within each HIV-1 Env pseudo virus (n=28) were identified by using N-Glycosite online software. The positions of the glycosylation sites relative to the relevant HXB2 reference sequence coordinates were generated (Fig. S1) . Comparisons of the neutralization sensitivity between the viruses were categorized based on the glycan positions at the N295, N137 and N332 sites. To determine the association of N322 glycan with broad neutralization, the 28-virus panel was divided into 2 groups: with and without a glycan site at amino acid position 332 (N332). It was found that the ID 50 titre of LT*VNP04 (Fig. 3c, P=0 .017) and TP*14 (Fig. 3d, P=0 .013) was significantly higher among the N332À virus group. However, the ID 50 titres of LT*VNP03 (Fig. 3a, P=0 .54) and LT*VNP20 (Fig. 3b, P=0 .10) did not differ significantly between the N332+ and N332À virus groups. Next, we investigated the N137 and N295 glycan position and its association with the plasma neutralization response from broad neutralizers. The plasma ID 50 titre showed no association between the N137+ and N137À virus groups (Fig. 3e-h ) and similar observations were recorded among the N295+ and N295À
virus groups (Fig. 3i-k) . The epitope specificities of the plasma samples from broad neutralizers are summarized in Table 8 .
DISCUSSION
In the present study, we investigated the HIV-1 neutralization response from a cohort of 70 ART-naïve HIV-1 subtype C-infected individuals with different disease progression profiles, i.e. viraemic controllers, viraemic non-progressors and typical progressors. Overall, 20 % of the individuals (14 out of 70 individuals) demonstrated bnAb responses that could neutralize 50 % of the HIV-1 isolates from a panel of 30 viruses. This frequency of potent bnAb response was consistent with recent findings among HIVinfected individuals [9, 19] . Of the 14 bnAb producers, we were able to identify 4 broad neutralizers with a neutralization breadth !70 % and a neutralization potency (GMT Broad neutralizers do not target V1/V2 and V3 glycan-specific antibodies. The epitope specificities of plasma samples from four broad neutralizers were determined using point-mutant viruses. WT, wild-type; Mt, mutant. ID 50 values refer to the reciprocal dilution that conferred 50 % neutralization of viruses in a TZM-bl assay. ID 50 titre !500). Among the four broad neutralizers, three were viraemic non-progressors and one was a typical progressor. In concordance with recent reports [20, 21] , in this study the neutralization breadth and potency were found to be significantly higher in the viraemic non-progressors compared to the typical progressors. Since viraemic nonprogressors maintain a stable CD4 T cell count, the higher bnAb response among this group might be attributed to the availability of adequate CD4+ T helper cells to aid in the formation of a stable germinal centre [22] . Our study also suggests that other factors, such as decreased immune activation and enhanced CTL response, may contribute towards the control of disease progression in viraemic nonprogressors, as reported recently [21] ; however, this needs to be further substantiated using specific studies. Further, in agreement with previous reports [23, 24] , the viraemic controllers in our study showed poor neutralizing activity as compared to the typical progressors, which may be due to the insufficient levels and exposure of the viral antigen that drives the emergence of bnAb response [25, 26] .
We evaluated the plasma samples from four broad neutralizers to identify the neutralization target that facilitates broad and potent antibody response. To evaluate the frequency of neutralizing CD4bs antibodies, we compared the binding activities to core proteins exposing the CD4bs, binding to soluble trimetric Env glycoprotein's RSC3 and ability to block CD4 binding in competition assays. In contrast to previous mapping studies, we observed no CD4bs activity among the broad neutralizers [16, 27] . This may be due to the requirement for a high level of somatic hypermutation (SHM) and the utilization of a unique variable heavy-chain region by CD4bs antibodies, which limit the probability of developing such CD4bs bnAbs [28, 29] .
The membrane proximal external region (MPER) of HIV-1 is also an important vaccine target. Several studies have demonstrated the existence of MPER antibodies within broad neutralizers in plasma samples [30, 31] . However, none of the broad neutralizers identified in our study showed an MPER-specific neutralization response, which is in concordance with a recent report that suggestedthat anti-MPER antibodies only occur rarely [27] , owing to their polyreactive nature [32] .
Further, anti-PG9/PG16-site antibodies have been shown to mediate breadth in some broad neutralizers [33, 34] . These antibodies require the presence of an N-linked glycan (at the N160 residue) in the V1V2 region of the envelope for potent neutralization [35] . In this regard, the association between the presence of anti-PG9/PG16-site specific antibodies and neutralization breadth was evaluated in the identified broad neutralizers, wherein it was found none of the plasma samples were sensitive to the removal of N160 glycan, indicating the absence of anti-PG9/PG16 antibodies. Additionally, recent studies indicated that R166 epitope is a possible target of HIV-1 bnAbs, for instance the CAP256-VRC26 lineage antibodies [36] , although none of the broad neutralizers identified in this study exhibited a specific response to the R166 epitope, which might be due to the engagement of rare germ line B cells among the CAP256-VRC26 lineage antibodies [37] , which are not frequently elicited among HIV-infected individuals [38] .
Anti-V3 antibodies are present in the sera of virtually all individuals infected with HIV-1 virus [39] . Several V3-specific bnAbs have been isolated [40] and are well-known for their ability to cross-neutralize [41] . The anti-V3/glycan class of antibodies primarily target the conserved [42] N332/high-mannose patch epitope region [43, 44] . Therefore, to detect V3 glycan-specific response, plasma samples from the identified broad neutralizers were tested with N301A and N332A mutant viruses; however, in contrast to recent findings, none of the broad neutralizers exhibited a neutralization response against the N332 supersite [45] [46] [47] . Further, as per the virus glycan analysis, two of the broad neutralizers (LT*VNP04 and TP*14) showed significantly enhanced sensitivity towards viruses that lack N332 glycan. This observation is in agreement with the recent studies that indicated that the antibodies are able to utilize promiscuous glycan in the absence of N332 glycan [48] , which is associated with enhanced neutralization response among broad neutralizers [43] . However, the top neutralizers (LT*VNP03 and LT*VNP20) in our study were found to be independent of the N332 glycan. This may be due to escape from the initial N332 antibody response, with subsequent loss of N332 glycan and maturation of plasma response to tolerate this escape mutation by switching the glycan position to N334 among broad neutralizers [46, 49] . Futher, none of the four broad neutralizers depended on either N295 or N137 glycan, which target the high-mannose patch region [48] , although this finding needs to be further validated by molecular analysis of the viral sequence (to detect any mutations in the viral genome among these individuals).
Conclusion
Our study documents the broad neutralization response among HIV-1 subtype C-infected individuals from southern India. In comparison to typical progressors, the viraemic non-progressors analysed in this study were found to be potent bnAb producers. The neutralization response was found to possess unique specificities as compared to the already known neutralizing epitopes. Thus, this study warrants further investigation of the molecular characteristics of the virus and more epitope mapping, which may provide critical insights into the development of the broad neutralization response among HIV-infected individuals and lead to the identification of novel bnAbs from Indian HIV-1 subtype-C-infected individuals.
METHODS

Study design
This was a cross-sectional study wherein 70 ART-naïve HIV-1 subtype C-infected individuals at different stages of disease progression (viraemic controllers, viraemic nonprogressors and typical progressors) were enrolled at the YRG Center for AIDS Research and Education (YRG CARE), Chennai, India. The study obtained ethical approval from the Institutional Review Board of YRG CARE. Written informed consent was obtained from all of the participants. Twenty-four micro litres of blood was collected from each participant in k3-EDTA blood collection tubes (Beckton Dickinson, USA). The samples were processed for the separation of plasma and were stored at À70 C until further use. On the basis of absolute CD4+ T cell counts, viral load estimations and the duration of the disease (post-diagnosis), the participants were broadly categorized as typical progressors (n=29) and long-term non-progressors (n=41), with the latter being sub-divided into viraemic controllers (LT*VC, n=20) and viraemic non-progressors (LT*VNP, n=21). For the current analysis, three distinct study groups were considered, as detailed below.
(1) <Viraemic controllers: individuals with >7 years of HIV-1 infection (post-diagnosis), asymptomatic with CD4+ T cell count >500 cells µl À1 and HIV-1 plasma viral load <5000 copies ml À1 [50] . (2) Viraemic non-progressors: individuals with >7 years of HIV-1 infection (post-diagnosis), asymptomatic with CD4+ T cell count >500 cells µl À1 and HIV-1 plasma viral load of at least 10 000 copies ml [51] . (3) Typical progressors: individuals with 3-7 years of HIV-1 infection (post-diagnosis), asymptomatic with CD4+ T cell count <500 cells µl À1 and HIV-1 plasma viral load >10 000 copies ml À1 [52] .
HIV-1 neutralization assay
The measurement of neutralization antibodies was carried out as a function of reductions in luciferase reporter gene expression after a single round of infection in TZM-bl cells as reported earlier [53] . Patient plasma specimens were heat-inactivated at 56 C for 30 min prior to use. Plasma specimens were threefold serially diluted with a starting dilution of 1 : 20 in Dulbecco's modified Eagle's medium (Gibco, Carlsbad, CA, USA) and 10 % foetal bovine serum (Hyclone Laboratories, South Logan, UT, USA). Each HIV-1 Env pseudovirus preparation was titrated to determine the optimal TCID dilution by using TZM-bl cells. Fifty micro litres of each virus was added to the diluted plasma samples, and this was followed by incubation for 45-90 min at 37 C in 5 % CO 2 environment. The TZM-bl cell monolayer was trypsinized after 1 h and 10 000 cells were seeded per well in 100 µl of growth media and incubated at 37 C in 5 % CO 2 environment. A virus control (pseudovirus and cells) and a cell control (only cells) well were assigned for each assay plate. After 48 h of incubation, 150 µl of supernatant was discarded from each well and 100 µl of substrate (BriteLite plus Reporter Gene Assay System, PerkinElmer Life and Analytical Sciences, Shelton, CT, USA) was added to each well; this was followed by incubation for 2 min. The lysed suspension at a volume of 150 µl for each well was transferred into a 96-well black solid plate (Costar Corning, New York, USA) for the measurement of relative luminescence units (RLUs) using a luminometer (VICTOR X3 Multilabel Plate Reader, PerkinElmer Life and Analytical Sciences, Turku, Finland). The neutralizing antibody titres were expressed as reciprocals of the plasma dilutions required to reduce the RLUs by 50 % compared to those of the pseudovirus control wells after the subtraction of background (cell control) RLUs. Fifty per cent inhibitory dilutions (ID 50 ) were calculated based on a curve fit to each neutralization assay in the excel macro software tool kindly provided Dr Montefiori, Duke University, Durham, USA. All of the study specimens were assayed against standard murine leukaemia virus (MLV) containing pSG3D env backbone plasmid to rule out the presence of antiretroviral (ARV) drugs.
Epitope mapping
We examined the epitope specificity by using point-mutant viruses with substitution of known target glycan amino acids in the V2 and V3 regions, and also by peptide/protein completion neutralization assays through the addition of RSC3 core protein, MPER and V3 peptides.
Epitope mapping using point mutants A standard neutralization assay was performed against mutated HIV-1 Env pseudoviruses harbouring point mutations in known epitopes in the gp120 variable regions: V2 regions N160A and R166A, and and V3 regions N301A and N332A. The clade C HIV-1 25 711 env was used as background to produce point-mutant viruses. The glycandependent neutralization was assessed by comparing the neutralization of HIV-1 25711 Env pseudovirus (wild-type) and its glycan knock-out variant as described previously [17] . All of the env point mutants were generously provided by Dr Jayanta Bhattacharya, HIV Vaccine Translational Research Laboratory, NCR Biotech Science Cluster, Translational Health Science and Technology Institute, Faridabad, Haryana, India through IAVI collaboration.
Peptide/protein inhibition of neutralization Peptide/protein competition neutralization assays were performed in the same assay format as the neutralization assay as described previously [54] . Competition neutralization was determined by adding 25 µg ml À1 of peptide/protein competitor to a threefold serial dilution of the plasma for probe with a concentration of 25 µg ml À1 in the protein competition assay as previously described [55] . The RSC3 (cat# 12042) probe was obtained from NIH AIDS Reference Reagent Program, NIAID NIH. This protein was designed to preserve the antigenic structure of the CD4-binding site of gp120 while removing other antigenic regions. RSC3 is based on the HXB2 Ds12F123 stabilized core. Variable regions 1-3 were removed. Competition was observed and considered to significant when the addition of peptide/protein resulted in a greater than threefold decrease in the neutralizing capacity of the antibody.
Detection of binding antibodies towards the CD4-binding site and the MPER-specific region Briefly, polystyrene flat-bottom 96-well microtitre plates were coated with test peptides (RSC3 and MPER peptide) with a final concentration of 1 µg ml À1 and kept at 4 C overnight. After incubation, the plates were washed four times with PBST (0.05 % Tween 20) using the ELISA Washer (MRW-Dynex). The wells were blocked with 200 µl of assay buffer and then incubated at 37 C for 1 h, with this being followed by four washes with PBST. The diluted specimens at 50 µl volume and 1 : 20 dilution were added to each well and incubated at 37 C for 1 h. After incubation the wells were washed four times with PBST, with this being followed by the addition of 50 µl of anti-human IgG peroxidase conjugate (1 : 4000). After incubation at 37 C for 1 h, the wells were washed four times with PBST. Then 200 µl of OPD substrate was added to the each well and they were then kept in the dark for 30 min at room temperature. After incubation, 50 µl of stop solution was added before measurement at 450 nm using an ELISA Reader (VICTOR X3 multiplate reader). The raw data were exported to an Excel spreadsheet and the positive cut-off was calculated by using the formula (NC mean+3 SD). The reactive specimens were tested in triplicate to confirm their positivity [56] .
CD4+ T cell enumeration
The CD4+ T cell counts in peripheral blood were measured by flow cytometry using FACS Count (Becton Dickinson, CA, USA) as per the manufacturer's instructions.
Viral load
The viral load in plasma was measured using the quantitative HIV-1 RNA Abbott Real-Time PCR (RT-PCR) m2000rt system (Abbott Molecular, CA, USA) as per the manufacturer's instructions. The viral load was measured as copies per millilitre (ml). The laboratory's detectable range was between 40 and 10 million copies per ml. The median and interquartile ranges (IQRs) were calculated for each group.
N-linked glycan analysis N-linked glycan among the HIV-1 Env pseudo virus (n=28) were identified by using gp160 sequences downloaded from the Compile, Analyse and Tally NAb Panels (CATNAP) database in the FASTA format (https://www.hiv.lanl.gov/ components/sequence/HIV/neutralization/index.html). The FASTA file was uploaded onto the N-Glycosite online software. The numbers of PNGS and the numbers of NXT or NXS motifs were identified using N-Glycosite at the Los Alamos HIV database website http://www.hiv.lanl.gov/content/sequence/GLYCOSITE/glycosite.html.
Reagents
The molecular clones of the HIV-1 Env pseudoviruses used in this study were a kind gift from Dr Hagen von Briesen, Fraunhofer Institute for Biomedical Engineering (IBMT), Sulzbach, Germany and from Dr David Montefiori, Laboratory for AIDS Vaccine Research andDevelopment, Duke University Medical Center, Durham, USA. The TZM-bl cells were kindly provided by Dr John Kappes and Dr Xiaoyun Wu as per the NIH AIDS Reagent Program. These were HeLa cell clones genetically engineered to express CD4, CXCR4 and CCR5 and contained integrated reporter genes for firefly luciferase and E. coli galactosidase under the control of an HIV-1 long terminal repeat (LTR). The human anti-gp120 carbohydrate-specific mAb 2G12, the human anti-gp41 mAb 2F5 and 4E10, the recombinant sCD4 and the HIV IgG were kindly provided by Dr David C. Montefiori, Duke University Medical Centre, Durham, NC, USA.
Statistical analyses
The descriptive statistics median and IQR were calculated for age and clinical characteristics. The neutralization response was considered to be positive if the neutralization titre (inhibitory dilution, ID 50 ) value was >100. The MannWhitney U test was used to compare the neutralization breadth and potency between viraemic non-progressors and typical progressors. These statistical analyses were performed using GraphPad Prism software (version 5.0; GraphPad Software, San Diego, CA, USA). A P-value of <0.05 was considered to be statistically significant.
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